A recent study published in the Journal of Controlled Release demonstrated a novel method for delivering anti-cancer drugs conjugated to modified cell-penetrating peptides across the blood-brain ...

There are about 106 peptide and nanobody drug conjugates in active development, and around 63% of them are still preclinical, according to a 2026 Citeline analysis of Pharmaprojects data.¹ For most of ...

A single patient with one of the rarest and most aggressive salivary gland malignancies has provided oncologists with an unexpected glimpse of what may become a new therapeutic avenue for tumors that ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier system that delivers therapeutic antibodies directly to target antigens inside ...

Westlake Therapeutics (Hangzhou) Co. Ltd. and affiliated organizations have reported the design and preclinical characterization of novel erythrocytes conjugated to major histocompatibility complex ...

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in ...

Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to ...

Effect of new strains of rotaviruses on PD1 and PD-L1 expression on peripheral blood T cells. The mobilization of endogenous bi-specific natural killer T-like cells and independent of glucocorticoid ...

A multicenter Central European real-world study finds sacituzumab govitecan delivers meaningful survival benefit and manageable toxicity in heavily pretreated metastatic triple-negative breast cancer ...

A conjugated or labeled antibody is a polyclonal or monoclonal antibody with an attached reporter molecule that generates a signal through color, fluorescence, radioactivity, or enzymatic activity, ...